Nektar Therapeutics (NKTR)
NASDAQ:NKTR
Want to see NKTR full AI Analyst Report?
NKTR Stock Chart & Stats
$84.86
-$0.04(-3.36%)
At close: 4:00 PM EST
$84.86
-$0.04(-3.36%)
Day’s Range― - ―
52-Week Range$7.99 - $109.00
Previous CloseN/A
Volume706.47K
Average Volume (3M)1.17M
Market Cap
$2.20B
Enterprise Value$1.28B
Total Cash (Recent Filing)$568.60M
Total Debt (Recent Filing)$143.43M
Price to Earnings (P/E)―
Beta3.61
Next Earnings
Aug 06, 2026EPS Estimate
-2.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.42
Shares Outstanding33,786,034
10 Day Avg. Volume902,087
30 Day Avg. Volume1,170,177
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)7.94
Price to Sales (P/S)12.91
P/FCF Ratio-3.42
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue23.04
Enterprise Value/Gross Profit23.19
Enterprise Value/Ebitda-10.67
Forecast
1Y Price Target
$154.33Price Target Upside81.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-9.06
Revenue Forecast (FY)$41.22M
Bulls Say, Bears Say
Bulls Say
Clear Phase III Path For REZPEGDefined pivotal timelines and a three‑trial registrational design materially reduce development uncertainty versus vague plans. A clear program enables focused resource allocation, regulatory planning and partner/commercial preparation, improving the probability of progressing to approval over 2–3 years.
Strong Pro Forma Liquidity And RunwayHaving >$1B pro forma and runway into Q3 2028 gives the company durable funding to complete planned Phase III starts and early execution without imminent financing. This reduces near‑term dilution risk, supports manufacturing and enrollment investments, and provides negotiating leverage with partners.
Favorable Safety And Differentiated MOAA differentiated Treg‑stimulating mechanism with a cleaner safety profile versus JAKs is a sustainable competitive advantage for chronic indications. Better tolerability supports broader prescribing, payer acceptance and longer treatment durations, which can drive durable market share if efficacy is confirmed in Phase III.
Bears Say
Persistent Negative Cash Flow And Heavy BurnSustained negative operating and free cash flow forces reliance on external financing or existing reserves, increasing dilution and refinancing risk. Over multiple quarters this constrains strategic optionality, elevates vulnerability to trial delays, and can pressure R&D prioritization and partner negotiations.
Regulatory And Endpoint Uncertainty In Alopecia AreataUnresolved regulator alignment on pivotal trial requirements can force additional studies or altered endpoints, materially extending timelines and costs. Such structural uncertainty affects program risk, potential approval pathways, and the company's ability to plan commercial launches or secure definitive partnerships.
Global Phase III Execution & Enrollment RiskLarge, multinational pivotal trials introduce sustained operational risks—site activation, CRO oversight and variable enrollment—that can delay readouts and inflate costs. For a small biotech, execution capability is a durable constraint that can determine program timelines and financing needs.
Nektar Therapeutics News
NKTR FAQ
What was Nektar Therapeutics’s price range in the past 12 months?
Nektar Therapeutics lowest stock price was $7.99 and its highest was $109.00 in the past 12 months.
What is Nektar Therapeutics’s market cap?
Nektar Therapeutics’s market cap is $2.20B.
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 68 days.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on May 07, 2026. The company reported -$1.82 earnings per share for the quarter, missing the consensus estimate of -$1.582 by -$0.238.
Is Nektar Therapeutics overvalued?
According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued.
Does Nektar Therapeutics pay dividends?
Nektar Therapeutics does not currently pay dividends.
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -2.04.
How many shares outstanding does Nektar Therapeutics have?
Nektar Therapeutics has 33,786,034 shares outstanding.
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of -$1.82 in its last earnings report, missing expectations of -$1.582. Following the earnings report the stock price went down -1.775%.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Currently, no hedge funds are holding shares in NKTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nektar Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$154.33 (81.87% Upside)
$154.33 (81.87% Upside)
Blogger Sentiment
Bullish
NKTR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 377.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $42.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.9%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
484.97%
12-Months-Change
Fundamentals
Return on Equity
-87.00%
Trailing 12-Months
Asset Growth
197.87%
Trailing 12-Months
Company Description
Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
NKTR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call delivered strong clinical progress and a clear, accelerated path to Phase III for REZPEG in atopic dermatitis and alopecia areata, supported by robust Phase IIb data (durable and deepening responses, EASI‑100 increases, SALT‑20 gains) and a fortified balance sheet (> $1B pro forma). Key positives include well‑defined Phase III designs, meaningful market opportunity, favorable safety signals versus JAK inhibitors, and additional pipeline and TrialNet collaboration in type 1 diabetes. Main concerns are typical biotech risks: ongoing net losses and increasing R&D spend as Phase III programs start, noncash interest expense, remaining regulatory/endpoint design questions (especially for AA and potential moderate AA expansion), and operational enrollment/execution risk for global trials. On balance, the positives (clinical validation, financing, program advancement) outweigh the near‑term financial and execution risks.View all NKTR earnings summariesNKTR Stock 12 Month Forecast
Average Price Target
$154.33
▲(81.87% Upside)
Technical Analysis
Wave Life Sciences
―
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Ownership Overview
3.07% Insiders
12.65% Mutual Funds
40.06% Other Institutional Investors
36.19% Public Companies and
Individual Investors